Research
Hormonal
Intranasal insulin administration improves memory and cognitive function in early Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients, particularly those who are ApoE-ε4 negative.
If you have early memory issues, ask your doctor about intranasal insulin trials. It may help memory, especially if you don't carry the ApoE-ε4 gene. It is safer than systemic insulin injections because it targets the brain directly without causing dangerous blood sugar drops.
ModerateQualifiesMEDIUM confidence
Intranasal delivery of insulin... is a safe and effective alternative to increase CSF insulin concentrations... studies have demonstrated the beneficial effects of insulin on memory function.
Why this rating
Based on multiple small clinical trials and animal studies, but results are mixed and genotype-dependent.
Source
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome
Bhumsoo Kim et al. · Experimental & Molecular Medicine · 2015
DOI 10.1038/emm.2015.3
narrative_reviewCited 341×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance (IR) is the primary mechanistic link connecting Metabolic Syndrome (MetS) to increased risk of Alzheimer's Disease (AD) and cognitive impairment, driven by impaired PI3K-Akt signaling, increased amyloid-beta (Aβ) production, and tau hyperphosphorylation.Good
- GLP-1 analogues (e.g., liraglutide, exenatide) show promise in animal models for reducing amyloid plaques, tau phosphorylation, and improving cognition, but human clinical trials have shown mixed or disappointing results so far.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →